Stereotaxis, Inc. - 8-K Filing
Stereotaxis reported Q1 2026 revenue of $6.3 million (down from $7.5 million in the prior year), with system revenue at $1.3 million and recurring revenue at $5.0 million. The company recorded a net loss of $5.9 million, compared to $5.8 million in Q1 2025. Gross margin was 60% for the quarter. Stereotaxis also announced FDA approvals for its MAGiC catheter and Synchrony system, as well as an acquisition agreement with Robocath. (Items: 2.02 Results of Operations and Financial Condition On May 12, 2026, Stereotaxis, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits)
Tickers: $STXS